8-K: Citius Oncology Raises $18M to Fund LYMPHIR Launch

Citius Oncology completed an $18 million concurrent registered direct offering and private placement to fund the commercial launch of its FDA-approved cancer therapy, LYMPHIR.

Summary

• Citius Oncology, Inc. completed a concurrent registered direct offering and private placement, raising approximately $18.0 million in gross proceeds.
• Net proceeds are approximately $15.2 million after deducting placement agent fees and other offering expenses.
• The offering included the sale of 1,284,404 shares of common stock at $1.09 per share and unregistered warrants to purchase an equal number of shares at an exercise price of $1.09.
• A concurrent private placement involved the sale of pre-funded warrants to purchase up to 15,229,358 shares and 15,229,358 common warrants, at a combined price of $1.0899 per unit.
• Pre-funded warrants are immediately exercisable at $0.0001 per share, while common warrants require stockholder approval and expire five years from that date.
• Existing warrants from July 2025 and September 2025, totaling 11,961,040 shares, had their exercise prices reduced to $1.09 per share and their exercisability made contingent on stockholder approval.
• The maturity date of a promissory note with Citius Pharmaceuticals, Inc. was amended to be contingent on Citius Oncology closing capital raises totaling at least $50 million or monetizing LYMPHIR royalties.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee of gross proceeds, expense reimbursements, and warrants to purchase 1,155,963 shares at an exercise price of $1.3625.

Sentiment

Score: 7

Explanation: The capital raise provides crucial funding for the commercial launch of an FDA-approved product, LYMPHIR, targeting a significant market. While there is dilution and the need for stockholder approval for some warrants, the overall sentiment is positive due to securing necessary capital for a key strategic initiative and the potential for future revenue generation.

Positives

• Successfully raised approximately $18.0 million in gross proceeds, strengthening the cash position.
• Net proceeds of $15.2 million are earmarked to support the commercial launch of LYMPHIR, an FDA-approved cancer immunotherapy.
• LYMPHIR targets a growing and underserved market estimated to exceed $400 million.
• The company possesses robust intellectual property protections for LYMPHIR, including orphan drug designation and pending patents for immuno-oncology combination therapy.
• The amendment to the promissory note from Citius Pharmaceuticals, Inc. provides flexibility by linking its maturity to future capital raises or LYMPHIR monetization, indicating ongoing support from the parent company.

Negatives

• The offering involves the issuance of new shares and warrants, which will result in dilution for existing shareholders.
• The exercisability of a significant portion of the warrants (common warrants and amended existing warrants) is contingent on obtaining stockholder approval, introducing an element of uncertainty.
• The exercise price of $1.09 per share for the new common warrants and the amended existing warrants is lower than the previous exercise prices of $1.32 and $1.84 for the existing warrants, indicating a potential downward adjustment in valuation or market price.
• Placement agent fees and other offering expenses totaled approximately $2.8 million ($18.0M $15.2M), representing a significant cost of capital.

Risks

• Need for substantial additional funds to fund operations for at least the next 12 months as a going concern.
• Ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream.
• Uncertainty regarding the estimated markets for LYMPHIR and product candidates and their acceptance.
• Ability to secure strategic partnerships and expand international access to LYMPHIR.
• Reliance on third-party logistics providers, distributors, and specialty pharmacies for commercial operations.
• Challenges in educating providers and payers, securing adequate reimbursement, and maintaining uninterrupted product supply.
• Post-marketing requirements and ongoing regulatory compliance related to LYMPHIR.
• Risks related to research and development activities for existing and new pipeline assets.
• Ability to procure cGMP commercial-scale supply.
• Ability to obtain, perform under, and maintain financing and strategic agreements.
• Ability to maintain Nasdaq's continued listing standards.
• Market and other conditions impacting the business.
• Patent and intellectual property matters.
• Ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis.
• Government regulation.
• Potential impact of future public health risks.

Future Outlook

Citius Oncology anticipates using the net proceeds to support the commercial launch of LYMPHIR and for general working capital. The company aims to successfully commercialize LYMPHIR, establish a sustainable revenue stream, secure strategic partnerships, and expand international access. Future plans also include continued research and development, ensuring cGMP commercial-scale supply, and maintaining Nasdaq listing standards. The company will seek stockholder approval for warrant exercisability within 90 days of closing and periodically thereafter.

Management Comments

• Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies.
• Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning.

Industry Context

The successful capital raise positions Citius Oncology to advance its recently FDA-approved cancer immunotherapy, LYMPHIR, into a market segment for cutaneous T-cell lymphoma (CTCL) that management identifies as growing and underserved. This move aligns with broader industry trends focusing on targeted oncology therapies and the commercialization of novel treatments for niche indications. The emphasis on intellectual property and potential for combination therapies suggests a strategy to build a strong market presence and competitive advantage within the immuno-oncology space.

Comparison to Industry Standards

• The offering price of $1.09 per share and the warrant exercise prices are 'at-the-market' under Nasdaq rules, indicating pricing aligned with current market conditions.
• The 7.0% placement agent fee is within the typical range for registered direct offerings in the biotechnology sector, which can vary based on deal size and market conditions.
• The requirement for stockholder approval for warrant exercisability is a standard corporate governance practice for certain equity issuances to prevent excessive dilution without shareholder consent, common among publicly traded companies.
• The beneficial ownership limitation of 4.99% or 9.99% is a common anti-takeover or anti-accumulation provision seen in similar financing agreements to prevent a single investor from gaining too much control without further disclosure or approval.

Corporate Governance

Related Party Transactions

• Amendment to a promissory note dated August 16, 2024, as previously amended on September 10, 2025, between Citius Oncology, Inc. (Payor) and Citius Pharmaceuticals, Inc. (Payee). The maturity date was amended to be contingent on Citius Oncology closing capital raises aggregating at least $50 million or royalty-backed monetization of LYMPHIR.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares and warrants. Existing warrants held by an institutional investor had their exercise price reduced, which could be seen as a negative for other shareholders if the original exercise price was higher than the current market price. However, the capital raise provides funding for LYMPHIR's commercialization, which could lead to future value creation.
• Investors (Purchasers in Offering): Acquired common stock and warrants at an 'at-the-market' price, with pre-funded warrants offering immediate exercisability. Benefited from reduced exercise prices on existing warrants.
• Employees: The funding supports the company's operations and the commercial launch of LYMPHIR, potentially stabilizing employment and creating new opportunities.
• Customers (Patients with CTCL): The funding supports the commercial launch of LYMPHIR, making an FDA-approved treatment more accessible.
• Creditors (Citius Pharmaceuticals, Inc.): The maturity of the promissory note is now tied to Citius Oncology's future capital raises or LYMPHIR monetization, indicating a flexible repayment schedule dependent on the subsidiary's success.

Next Steps

• Seek stockholder approval for the exercisability of common warrants and amended existing warrants within 90 days of the closing date, and every 90 days thereafter until obtained.
• File a registration statement with the SEC covering the resale of shares underlying the pre-funded warrants, common warrants, and placement agent warrants within 30 days of the Registration Rights Agreement date.
• Have the resale registration statement declared effective no later than 60 days (or 90 days if reviewed by SEC) following the Registration Rights Agreement date.
• Commercial launch of LYMPHIR.
• Continue efforts to establish a sustainable revenue stream for LYMPHIR.
• Pursue strategic partnerships and expand international access for LYMPHIR.
• Procure cGMP commercial-scale supply for LYMPHIR.

Key Dates

Recommendation

The capital raise is a necessary step for Citius Oncology to fund the commercial launch of its FDA-approved product, LYMPHIR, which targets a significant and underserved market. This provides a clear path for potential revenue generation. However, the offering involves significant dilution for existing shareholders, and the exercisability of a large portion of warrants is contingent on future stockholder approval, introducing uncertainty. The reduction in exercise price for existing warrants also suggests a lower valuation. While the funding is positive for operational continuity and product launch, the dilutive nature and the need for future approvals warrant a 'hold' recommendation, advising investors to monitor the commercialization progress of LYMPHIR and the outcome of stockholder approvals before making further investment decisions.

Keywords

Citius Oncology, CTOR, LYMPHIR, Registered Direct Offering, Private Placement, Warrants, Capital Raise, Oncology, Cancer Immunotherapy, CTCL, SEC Filing, Nasdaq, Biotechnology, Pharmaceuticals, Stockholder Approval, Dilution